Recombinant Human BTNL10/Butyrophilin-like 10 Fc Protein, CF

Recombinant Human BTNL10 Fc Chimera (Catalog # 10014-BT) inhibitsIFN-gamma secretion by human peripheral blood mononuclear cells in the presence ofanti-CD3 antibody. The ED50 for this effect is 1.5-7.5 μg/mL.

2 μg/lane of Recombinant Human BTNL10 was resolved with SDS-PAGE underreducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Bluestaining, showing bands at 48-55 kDa and 95-110 kDa, respectively.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human BTNL10/Butyrophilin-like 10 Fc Protein, CF Summary

• Details of Functionality: Measured by its ability to inhibit anti-CD3 antibody induced IFN-gamma secretion by human peripheral blood mononuclear cells (PBMC). The ED₅₀ for this effect is 1.5-7.5 μg/mL.
• Source: Human embryonic kidney cell, HEK293-derived human BTNL10 protein
  

  Human BTNL10 (Ser27-Gly149) Accession # A8MVZ5	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: A8MVZ5
• N-terminal Sequence: Ser27
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Purity Statement: Antigen Affinity-purified
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 40.6 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 48-55 kDa & 96-108 kDa (non-reducible dimer), reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, ≤ -20 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, ≤ -20 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Reconstitution Instructions: Reconstitute at 200 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human BTNL10/Butyrophilin-like 10 Fc Protein, CF

• BTN4
• BTNL10 butyrophilin-like 10
• BTNL10
• BUTR1

Background

Butyrophilin-like 10 (BTNL10) is a member of the BTN/MOG Ig-superfamily and functions as a negative regulator of immune cell activation (1). Human BTNL10 is a 291 amino acid (aa) type I transmembrane glycoprotein that contains a signal peptide followed by an extracellular domain (ECD), a transmembrane region, and a short cytoplasmic domain. The ECD of human BTNL10 features a single IgV and a poorly defined IgC domain. The IgV domain of human BTNL10 shares 53% and 52% sequence identity with the equivalent ECD domain of mouse and rat BTNL10, respectively. Although just recently identified, BTNL10 is one of only five butyrophilins conserved between human and mouse (2). While the complete immunological function of BTN/BTNL molecules is only beginning to emerge, they have been shown to be important in immunity by regulating T cell function (2-4). Recent efforts have focused on BTN/BTNL as potential therapeutic targets for a wide range of diseases (2-4). Currently, both the expression pattern and native function of BTNL10 remain unknown. Our data indicate that BTNL10 inhibits the human T cell activation, including IL-2, IFN- gamma secretion, and T cell proliferation.

1. Arnett, H.A. et al. (2007) J. Immunol. 178:1523.
2. Arnett, H.A. et al. (2012) Immunogenetics. 64:781.
3. Abeler-Dörner L. et al. (2012) Trends Immunol. 33(1):34.
4. Arnett, H.A. and Viney J.L. (2014) Nat Rev Immunol. 14(8):559.

Bioinformatics

• Uniprot:
  • A8MVZ5()